Genetic testing by cancer site: Skin

Cancer Journal (United States)

Volumn 18, Issue 4, 2012, Pages 372-380

  Gabree, Michele ^a   Seidel, Meredith ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

basal cell nevus syndrome; caf au lait macules; Hereditary melanoma; melanoma; neurofibroma; neurofibromatosis type 1; neurofibromatosis type 2; schwannomas

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MELANOCORTIN 1 RECEPTOR; PROTEIN P16; PROTEIN PATCHED 1;

BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; BIRT HOGG DUBE SYNDROME; BLOOD PRESSURE MONITORING; BRAIN TUMOR; CAFE AU LAIT SPOT; CALCIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER SUSCEPTIBILITY; COWDEN SYNDROME; FACIES; FAMILIAL CANCER; FAMILY HISTORY; GENE DELETION; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; GLIOMA; HUMAN; KIDNEY ARTERY STENOSIS; LEIOMYOMATOSIS; LENTIGO; MEDULLOBLASTOMA; MELANOMA; MOSAICISM; NEUROFIBROMA; NEUROFIBROMATOSIS; PERIPHERAL NEUROPATHY; PHENOTYPE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PULMONARY VALVE STENOSIS; RADIATION EXPOSURE; REVIEW; SKIN CANCER; SKIN MANIFESTATION; VISUAL ACUITY;

BASAL CELL NEVUS SYNDROME; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MELANOMA; NEUROFIBROMATOSIS 1; NEUROFIBROMATOSIS 2; SKIN NEOPLASMS;

EID: 84864586281     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3182624664     Document Type: Review

References (69)

1. Pilarski R. Cowden syndrome: a critical review of the clinical literature. J Genet Couns. 2009;18:13Y27.
2. Hobert JA, Eng C. PTEN hamartoma tumor syndrome: an overview. Genet Med. 2009;11:687Y694.
3. Menko FH, van Steensel MA, Giraud S, et al. Birt-Hogg-Dubé syndrome: diagnosis and management. Lancet Oncol. 2009;10:1199Y1206.
4. Kruger S, Kinzel M, Walldorf C, et al. Homozygous PMS2 germline mutations in two families with early-onset haematological malignancy, brain tumours, HNPCC-associated tumours, and signs of neurofibromatosis type 1. Eur J Hum Genet. 2008;16:62Y72.
5. Badeloe S, Frank J. Clinical and molecular genetic aspects of hereditary multiple cutaneous leiomyomatosis. Eur J Dermatol. 2009;19:545Y551.
6. Moline J, Eng C. Multiple endocrine neoplasia type 2: an overview. Genet Med. 13:755Y764.
7. Ferner RE. The neurofibromatoses. Pract Neurol. 10:82Y93.
8. Williams VC, Lucas J, Babcock MA, et al. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123:124Y133.
9. AsthagiriAR,ParryDM,Butman JA, et al.Neurofibromatosis type 2.Lancet. 2009;373:1974Y1986.
10. Beggs AD, Latchford AR, Vasen HF, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut. 59: 975Y986.
11. Borkowska J, Schwartz RA, Kotulska K, Jozwiak S. Tuberous sclerosis complex: tumors and tumorigenesis. Int J Dermatol. 50:13Y20.
12. Winship IM, Dudding TE. Lessons from the skinVcutaneous features of familial cancer. Lancet Oncol. 2008;9:462Y472.
13. Burger B, Cattani N, Trueb S, et al. Prevalence of skin lesions in familial adenomatous polyposis: a marker for presymptomatic diagnosis? Oncologist. 16:1698Y1705.
14. Evans DG, Farndon PA. Nevoid Basal Cell Carcinoma Syndrome. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. GeneReviewsTM [Internet]. Seattle WA: University of Washington, Seattle; 1993.
15. Leachman SA, Carucci J, Kohlmann W, et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol. 2009;61:677e1Y677e14.
16. Kremer KH, DiGiovana JJ. Xeroderma Pigmentosum. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. GeneReviewsTM [Internet]. Seattle, WA: University of Washington, Seattle; 1993.
17. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst. 1999;91:1310Y1316.
18. Dores GM, Curtis RE, Toro JR, et al. Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome. Cancer. 2008;113:3372Y3381.
19. Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 28:893Y901.
20. Hemminki K, Eng C. Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans. J Med Genet. 2004;41:801Y807.
21. Goldstein AM, Chidambaram A, Halpern A, et al. Rarity of CDK4 germline mutations in familial melanoma. Melanoma Res. 2002;12:51Y55.
22. Hayward NK. Genetics of melanoma predisposition. Oncogene. 2003;22:3053Y3062.
23. Goldstein AM, Chan M, Harland M, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 2006;66:9818Y9828.
24. Newton Bishop JA, Bataille V, Pinney E, et al. Family studies in melanoma: identification of the atypical mole syndrome (AMS) phenotype. Melanoma Res. 1994;4:199Y206.
25. Newton Bishop JA, Gruis NA. Genetics: what advice for patients who present with a family history of melanoma? Semin Oncol. 2007;34: 452Y459.
26. Bishop JN, Harland M, Randerson-Moor J, Bishop DT. Management of familial melanoma. Lancet Oncol. 2007;8:46Y54.
27. Bishop, DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002;94:894Y903.
28. Begg CB, Orlow I, Hummer AJ, et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst. 2005;97:1507Y1515.
29. Demenais F, Mohamdi H, Chaudru V, et al. Association of MC1R variants and host phenotypes with melanoma risk inCDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst. 102:1568Y1583.
30. Raimondi S, Sera F, Gandini S, et al. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer. 2008;122: 2753Y2760.
31. de Snoo FA,BishopDT,BergmanW, et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)Ypositive melanoma families. Clin Cancer Res. 2008;14:7151Y7157.
32. Randerson-Moor JA, Harland M,William S, et al. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet. 2001;10:55Y62.
33. Tsao H, Zhang X, Kwitkiwski K, et al. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol. 2000;136:1118Y1122.
34. Berg P, Wennberg AM, Tuominen R, et al. Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma. Melanoma Res. 2004;14:251Y255.
35. Aspinwall LG, Leaf SL, Kohlmann W, et al. Patterns of photoprotection following CDKN2A/p16 genetic test reporting and counseling. J Am Acad Dermatol. 2009;60:745Y757.
36. Aspinwall LG, Leaf SL, Dola ER, et al. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families. Cancer Epidemiol Biomarkers Prev. 2008;17:1510Y1519.
37. Eckerle Mize D, Bishop M, Reese E, Sluzevich J. Familial Atypical Multiple Mole Melanoma Syndrome. In: Riegert-Johnson DL, Boardman LA, Hefferon T, Roberts M, editors. Cancer Syndromes [Internet]. Bethesda, MD: National Center for Biotechnology Information (US); 2009.
38. Bartsch DK, Sina-Frey M, Lang S, et al. CDKN2A germline mutations in familial pancreatic cancer. Ann Surg. 2002;236:730Y737.
39. Verna EC, Hwang C, Stevens PD, et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res. 16:5028Y5037.
40. Lo Muzio, L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis. 2008;3:32.
41. Tom WL, Hurley MY, Oliver DS, et al. Features of basal cell carcinomas in basal cell nevus syndrome. Am J Med Genet A. 155A:2098Y2104.
42. Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 152A:327Y332.
43. Lupi O. Correlations between the sonic hedgehog pathway and basal cell carcinoma. Int J Dermatol. 2007;46:1113Y1117.
44. Yamamoto K, Yoshihashi H, Furuya N, et al. Further delineation of 9q22 deletion syndrome associated with basal cell nevus (Gorlin) syndrome: report of two cases and review of the literature. Congenit Anom (Kyoto). 2009;49:8Y14.
45. Pastorino L, Ghiorzo P, Nasti S, et al. Identification of a SUFU germline mutation in a family with Gorlin syndrome. Am J Med Genet A. 2009;149A:1539Y1543.
46. Fan Z, Li J, Du J, et al. A missense mutation in PTCH2 underlies dominantly inherited NBCCS in a Chinese family. J Med Genet. 2008;45: 303Y308.
47. Go JW, Kim SH, Yi SY. Basal cell nevus syndrome showing several histologic types of Basal cell carcinoma. Ann Dermatol. 23(suppl 1): S36YS40.
48. Kimonis VE, Mehta SG, Digiovanna JJ, et al. Radiological features in 82 patients with nevoid basal cell carcinoma (NBCC or Gorlin) syndrome. Genet Med. 2004;6:495Y502.
49. Amlashi SF, Riffaud L, Brassier G, Morandi X. Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature. Cancer. 2003; 98:618Y624.
50. Mohtasham N, Nemati S, Jamshidi S, et al. Odontogenic keratocysts in nevoid basal cell carcinoma syndrome: a case report. Cases J. 2009; 2:9399.
51. Ball A, Wenning J, Van Eyk N. Ovarian fibromas in pediatric patients with basal cell nevus (Gorlin) syndrome. J Pediatr Adolesc Gynecol. 24:e5Ye7.
52. Bossert T, Walther T, Vondrys D, et al. Cardiac fibroma as an inherited manifestation of nevoid basal-cell carcinoma syndrome. Tex Heart Inst J. 2006;33:88Y90.
53. Bree AF, Shah MR. Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS). Am J Med Genet A. 155A:2091Y2097.
54. Takahashi C, Kanazawa N, Yoshikawa Y, et al. Germline PTCH1 mutations in Japanese basal cell nevus syndrome patients. J Hum Genet. 2009;54:403Y408.
55. Casaroto AR, Loures DC, Moreschi E, et al. Early diagnosis of Gorlin-Goltz syndrome: case report. Head Face Med. 7:2.
56. Morse CB, McLaren JF, Roy D, et al. Ovarian preservation in a young patient with Gorlin syndrome and multiple bilateral ovarian masses. Fertil Steril. 96:e47Ye50.
57. Boyd KP, Korf BR, Theos A. Neurofibromatosis type 1. J Am Acad Dermatol. 2009;61:1Y14.
58. Yohay K. Neurofibromatosis types 1 and 2. Neurologist. 2006;12:86Y93.
59. Radtke HB, Sebold CD, Allison C, et al. Neurofibromatosis type 1 in genetic counseling practice: recommendations of the National Society of Genetic Counselors. J Genet Couns. 2007;16:387Y407.
60. Ahmad S, ed. Neurodegenerative Diseases. Vol. 724. Landes Bioscience and Springer Science+Business Media; 2012.
61. Patil S, Chamberlain RS. Neoplasms associated with germline and somatic NF1 gene mutations. Oncologist. 17:101Y116.
62. Kossler N, Stricker S, Rödelsperger C, et al. Neurofibromin (Nf1) is required for skeletal muscle development. Hum Mol Genet. 20: 2697Y2709.
63. Friedman, J. Neurofibromatosis 1. June 2, 2009. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1109. Accessed March 6, 2012.
64. Ardern-Holmes SL, North KN. Therapeutics for childhood neurofibromatosis type 1 and type 2. Curr Treat Options Neurol. 13:529Y543.
65. Ponder MMF, Hallowell N, Statham H, et al. Genetic counseling, reproductive behavior and future reproductive intentions of people with neurofibromatosis type 1 (NF1). J Genet Couns. 1998;7:331Y344.
66. Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis. 2009;4:16.
67. Goutagny S, Kalamarides M. Meningiomas and neurofibromatosis. J Neurooncol. 99:341Y347.
68. Baser ME, Friedman JM, Joe H, et al. Empirical development of improved diagnostic criteria for neurofibromatosis 2. Genet Med. 13:576Y581.
69. Evans DG, Raymond FL, Barwell JG, et al. Genetic testing and screening of individuals at risk of NF2. Clin Genet. 2011; [epub ahead of print] doi: 10.1111/j.1399-0004.2011.01816.x.